nach oben

Drugs

Erschienen in:

01.09.2010 | Adis Drug Evaluation

Bendamustine

A Review of its Use in the Management of Indolent Non-Hodgkin’s Lymphoma and Mantle Cell Lymphoma

verfasst von: Karly P. Garnock-Jones

Erschienen in: Drugs | Ausgabe 13/2010

Einloggen, um Zugang zu erhalten

Abstract

Bendamustine (bendamustine hydrochloride) is an alkylating agent indicated in several countries for the treatment of indolent non-Hodgkin’s lymphoma (NHL) and mantle cell lymphoma (MCL). While the precise mechanism of action of bendamustine is as yet unknown, it has limited cross resistance to other alkylating agents and appears to exert its antineoplastic effects via a different mechanism to that of other alkylating agents.

Bendamustine monotherapy was effective in treatment-refractory (including rituximab-refractory) indolent NHL or MCL. Moreover, bendamustine-based combination treatment was at least as effective as cyclophosphamide-based treatment, and bendamustine plus rituximab was at least as effective as cyclophosphamide, doxorubicin, vincristine plus prednisone (CHOP) plus rituximab, as first-line therapy in patients with indolent NHL or MCL. Treatment-refractory disease also appeared to respond favourably to bendamustine-containing combination treatment. In general, bendamustine was associated with a high overall response rate and a durable response.

The most common adverse events associated with bendamustine were haematological or gastrointestinal in nature, and most were of mild to moderate severity. Regimens that included bendamustine were also associated with a very low rate of alopecia compared with regimens that included other antineoplastic drugs.

In conclusion, bendamustine is a unique alkylating agent, which in clinical trials has demonstrated consistent efficacy and acceptable tolerability in patients with indolent NHL or MCL. It may be a particularly useful treatment option in patients with rituximab-refractory disease, but has also demonstrated efficacy as part of a first-line combination treatment. While further research is necessary to firmly establish the best place for bendamustine in the management of indolent NHL and MCL, it is a valuable addition to the pool of available treatments for these diseases.

Ekström-Smedby K. Epidemiology and etiology of non-Hodgkin lymphoma: a review. Acta Oncol 2006; 45(3): 258–71PubMedCrossRef

Aldoss IT, Blumel SM, Bierman PJ. The role of bendamustine in the treatment of indolent non-Hodgkin lymphoma. Cancer Management and Research 2009; 1: 155–65PubMedCrossRef

Merck. Non-Hodgkin lymphomas: Merck manual professional [online]. Available from URL: http://www.merck.com/mmpe/sec11/ch143/ch143c.html [Accessed 2010 May 6]

Goy A. Mantle cell lymphoma: Evolving novel options. Curr Oncol Rep 2007; 9(5): 391–8PubMedCrossRef

National Comprehensive Cancer Network. Clinical practice guidelines in oncology: non-Hodgkin’s lymphomas (V. 1.2010) [online]. Available from URL: http://www.nccn.org/professionals/physician_gls/PDF/nhl.pdf [Accessed 2010 May 6]

World Health Organisation. GLOBOCAN 2008: cancer incidence and mortality worldwide in 2008 [online]. Available from URL: http://globocan.iarc.fr/ [Accessed 2010 Aug 5]

American Cancer Society. Detailed guide: lymphoma, non-hodgkin type [online]. Available from URL: http://www.cancer.org/docroot/CRI/CRI_2_1x.asp?rnav=criov&dt=32 [Accessed 2010 May 6]

Tageja N, Nagi J. Bendamustine: something old, something new. Cancer Chemother Pharmacol 2010 Apr 8

National Cancer Institute. Adult non-Hodgkin lymphoma treatment (PDQ®): health professional version [online]. Available from URL: http://www.cancer.gov/cancertopics/pdq/treatment/adult-non-hodgkins [Accessed 2010 May 7]

10.

Cheson BD, Ashforth E. Newer strategies for overcoming rituximab resistance in non-Hodgkins lymphoma and chronic lymphocytic leukemia. Clin Adv Hematol Oncol 2009; 7 (2 Suppl. 5): 8–16

11.

Cephalon Inc. Treanda® (bendamustine hydrochloride) for intravenous infusion: US prescribing information [online]. Available from URL: http://www.treanda.com/docs/TREANDA_final_P1.pdf [Accessed 2010 Apr 16]

12.

Cheson BD, Wendtner CM, Pieper A, et al. Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel. Clin Lymphoma Myeloma Leuk 2010 Feb; 10(1): 21–7PubMedCrossRef

13.

Cephalon Inc. Cephalon receives FDA approval for Treanda to treat patients with relapsed indolent non-Hodgkin’s lymphoma [media release]. 2008 Oct 31 [online]. Available from URL: http://www.cephalon.com/media/news-releases/ [Accessed 2010 May 7]

14.

SymBio Pharmaceuticals Limited. Bendamustine HCl (SyB L-0501) approved in Singapore and Hong Kong — gains momentum for business expansion in Asia Pacific [online]. Available from URL: http://www.symbiopharma.com/en/news/100127e.pdf [Accessed 2010 Jul 29]

15.

European Medicines Agency. Questions and answers on Levact and associated names (bendamustine hydrochloride, 2.5 mg/ml, powder for concentrate for solution for infusion) [online]. Available from URL: http://www.ema.europa.eu/pdfs/human/referral/Levact/ha_291238q&a.pdf [Accessed 2010 May 21]

16.

SymBio Pharmaceuticals Limited. SymBio Announces NDA Submission for SyB L-0501 (bendamustine hydrochloride) [online]. Available from URL: http://www.symbiopharma.com/en/news/091030e.pdf [Accessed 2010 May 7]

17.

Plosker GL, Carter NJ. Bendamustine: a review of its use in the management of indolent non-Hodgkin lymphoma. Drugs 2008; 68(18): 2645–60PubMedCrossRef

18.

Barman Balfour JA, Goa KL. Bendamustine. Drugs 2001; 61(5): 631–8CrossRef

19.

Gandhi V. Metabolism and mechanisms of action of bendamustine: rationales for combination therapies. Semin Oncol 2002 Aug; 29 (4 Suppl. 13): 4–11PubMedCrossRef

20.

Konstantinov SM, Kostovski A, Topashka-Ancheva M, et al. Cytotoxic efficacy of bendamustine in human leukemia and breast cancer cell lines. J Cancer Res Clin Oncol 2002 May; 128(5): 271–8PubMedCrossRef

21.

Schwänen C, Hecker T, Hubinger G, et al. In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia. Leukemia 2002 Oct; 16(10): 2096–105PubMedCrossRef

22.

Nowak D, Boehrer S, Brieger A, et al. Upon drug-induced apoptosis in lymphoma cells X-linked inhibitor of apoptosis (XIAP) translocates from the cytosol to the nucleus. Leuk Lymphoma 2004 Jul; 45(7): 1429–36PubMedCrossRef

23.

Roué G, López-Guerra M, Milpied P, et al. Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling. Clin Cancer Res 2008 Nov 1; 14(21): 6907–15PubMedCrossRef

24.

Leoni LM, Bailey B, Reifert J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 2008 Jan; 14(1): 309–17PubMedCrossRef

25.

Chow KU, Boehrer S, Geduldig K, et al. In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin’s lymphomas using combinations of established cytotoxic drugs with bendamustine. Haematologica 2001 May; 86(5): 485–93PubMed

26.

Zong W-X, Ditsworth D, Bauer DE, et al. Alkylating DNA damage stimulates a regulated form of necrotic cell death. Genes Dev 2004; 18: 1272–82PubMedCrossRef

27.

Strumberg D, Harstrick A, Doll K, et al. Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anticancer Drugs 1996 Jun; 7(4): 415–21PubMedCrossRef

28.

Chow KU, Nowak D, Boehrer S, et al. Synergistic effects of chemotherapeutic drugs in lymphoma cells are associated with down-regulation of inhibitor of apoptosis proteins (IAPs), prostate-apoptosis-response-gene 4 (Par-4), death-associated protein (Daxx) and with enforced caspase activation. Biochem Pharmacol 2003; 66: 711–24PubMedCrossRef

29.

Chow KU, Sommerlad WD, Boehrer S, et al. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica 2002; 87: 33–43PubMed

30.

Kanekal S, Crain B, Elliott G. SDX-105 (Treanda™) enhances the tumour growth inhibitory effect of rituximab in Daudi lymphoma xenografts [abstract no. 4580]. Blood 2004; 104: 229b

31.

Schoffski P, Seeland G, Engel H, et al. Weekly administration of bendamustine: a phase I study in patients with advanced progressive solid tumours. Ann Oncol 2000 Jun; 11(6): 729–34PubMedCrossRef

32.

Kath R, Blumenstengel K, Fricke HJ, et al. Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia. J Cancer Res Clin Oncol 2001 Jan; 127(1): 48–54PubMedCrossRef

33.

Gaul L, Mandl-Weber S, Baumann P, et al. Bendamustine induces G2 cell cycle arrest and apoptosis in myeloma cells: the role of ATM-Chk2-Cdc25A and ATM-p53-p21-pathways. J Cancer Res Clin Oncol 2008 Feb; 134(2): 245–53PubMedCrossRef

34.

Ogura M, Uchida T, Taniwaki M, et al. Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Science. Epub 2010 May 27

35.

Rasschaert M, Schrijvers D, Van den Brande J, et al. A phase I study of bendamustine hydrochloride administered once every 3 weeks in patients with solid tumors. Anti-cancer Drugs 2007; 18: 587–95PubMedCrossRef

36.

Rasschaert M, Schrijvers D, Van den Brande J. A phase I study of bendamustine hydrochloride administered day 1 + 2 every 3 weeks in patients with solid tumours. Br J Cancer 2007; 96: 1692–8PubMedCrossRef

37.

Owen JS, Melhem M, Passarell JA, et al. Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin’s lymphoma. Cancer Chemother Pharmacol 2010 Feb 6

38.

Teichert J, Baumann F, Chao Q, et al. Characterization of two phase I metabolites of bendamustine in human liver microsomes and in cancer patients treated with bendamustine hydrochloride. Cancer Chemother Pharmacol 2007; 59: 759–70PubMedCrossRef

39.

Teichert J, Sohr R, Baumann F, et al. Synthesis and characterization of some new phase II metabolites of the alky-lator bendamustine and their identification in human bile, urine and plasma from patients with cholangiocarcinoma. Drug Metab Dispos 2005; 33(7): 984–92PubMedCrossRef

40.

Heider A, Niederle N. Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin’s lymphomas. Anticancer Drugs 2001 Oct; 12(9): 725–9PubMedCrossRef

41.

Heider A, Kress M, Niederle N. Bendamustin as second-line therapy in patients with relapsed low grade non-Hodgkin’s lymphoma and multiple myeloma [in German]. Tumor Diagnostik Und Therapie 1997; 18(3): 71–5

42.

Omachi K, Ando K, Ogura M, et al. Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Science. Epub 2010 May 29

43.

Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a multicenter study. Cancer 2010; 116(1): 106–14PubMed

44.

Friedberg JW, Cohen P, Chen L, et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin’s lymphoma: results from a phase II multi-center, single-agent study [published erratum appears in J Clin Oncol 2008 Apr; 26 (11): 1911]. J Clin Oncol 2008 Jan; 26(2): 204–10PubMedCrossRef

45.

Herold M, Schulze A, Niederwieser D, et al. Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin’s lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19). J Cancer Res Clin Oncol 2006 Feb; 132(2): 105–12PubMedCrossRef

46.

Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany) [abstract no. 405]. Blood 2009 Nov; 114(22): 168

47.

Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin’s lymphoma. J Clin Oncol 2005 May; 23(15): 3383–9PubMedCrossRef

48.

Rummel MJ, Atta J, Welslau M, et al. Bendamustine and rituximab are effective in the treatment of relapsed or refractory indolent and mantle-cell lymphoma: long-term follow-up of a phase II study [abstract no. 8034]. J Clin Oncol 2007 Jun; 25 (18 Suppl.): 449

49.

Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin’s lymphoma. J Clin Oncol 2008 Sep; 26(27): 4473–9PubMedCrossRef

50.

Weide R, Hess G, Koppler H, et al. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas: a multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG). Leuk Lymphoma 2007 Jul; 48(7): 1299–306PubMedCrossRef

51.

University of Giessen. Bendamustine plus rituximab versus CHOP plus rituximab [Clinicaltrials.gov identifier NCT00991211]. US National Institutes of Health, Clinical Trials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2010 Apr 22]

52.

Dreyling M. Newly diagnosed and relapsed follicular lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20 Suppl. 4: iv1 19–20CrossRef

53.

Hagemeister F. Rituximab for the treatment of non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia. Drugs 2010 Feb 12; 70(3): 261–72PubMedCrossRef

54.

Cheson BD, Kroll ML. Bendamustine induced neurotoxicity. Clin Adv Hematol Oncol 2009 Nov; 7(11): 743–6PubMed

55.

Cephalon Inc. Study of bendamustine hydrochloride and rituximab (BR) compared with R-CVP or R-CHOP in the first-line treatment of patientswith advanced indolent non-Hodgkin’s lymphoma (NHL) or mantle cell lymphoma (MCL)-referred to as the BRIGHT study [ClinicalTrials. gov identifier NCT00877006]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2010 May 20]

56.

Genentech. A study to investigate the efficacy and safety of bendamustine compared with bendamustine + RO5072759 (GA101) in patients with rituximab-refractory, indolent non-Hodgkin’s lymphoma (GADOLIN) [ClinicalTrials. gov identifier NCT01059630]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2010 May 24]

57.

GlaxoSmithKline. Ofatumumab and bendamustine combination therapy compared with bendamustine monotherapy in indolent B-cell non-Hodgkin’s lymphoma (NHL) unresponsive to rituximab or a rituximab-containing regimen (COMPLEMENT A+B) [ClinicalTrials.gov identifier NCT01077518]. US National Institutes of Health, Clinical Trials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2010 May 24]

58.

Koenigsmann M, Knauf WU, Herold M, et al. Fludarabine and bendamustine in refractory and relapsed indolent lymphoma: a multicenter phase I/II trial of the East German Society of Hematology and Oncology (OSHO). Leuk Lymphoma 2004; 45(9): 1821–7PubMedCrossRef

59.

Moosmann P, Heizmann M, Kotrubczik N, et al. Weekly treatment with a combination of bortezomib and bendamustine in relapsed or refractory indolent non-Hodgkin lymphoma. Leuk Lymphoma 2010; 51(1): 149–52PubMedCrossRef

Titel: Bendamustine
A Review of its Use in the Management of Indolent Non-Hodgkin’s Lymphoma and Mantle Cell Lymphoma
verfasst von: Karly P. Garnock-Jones
Publikationsdatum: 01.09.2010
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 13/2010
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.2165/11205860-000000000-00000

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 13/2010

Pyelonephritis in Pregnancy

Novel Antiretroviral Combinations in Treatment-Experienced Patients with HIV Infection

Opioid Formulations Designed to Resist/Deter Abuse

Pharmacoeconomic Considerations in the Treatment of Multiple Sclerosis

Octreotide Long-Acting Release (LAR)

Tapentadol Immediate Release